According to McKinsey, the worldwide value of pharmaceutical goods traded has grown sixfold, from $113 billion in 2000 to $629 billion in 2019. In the midst of this rapid growth, supply chains have become increasingly global, complex, and opaque, and the COVID-19 pandemic has aggravated the circumstance. Pharmaceutical companies are increasingly focused on developing a manufacturing network strategy that optimizes resources, enhances resilience, and confers a competitive edge.

One of the global-leading companies, Siegfried is pacesetting the life science industry by devoting itself to offering an ever-growing, efficient, cost-competitive, and high-quality medicine manufacturing process tackling the challenge of drug security, as well as achieving sustainable growth. 

Wolfgang Wienand, CEO of Siegfried, says, “As an outcome of having built that global network, we are now one of the suppliers who can deliver upon the promise of supplying on a global scale. It is our ambition to take the right decisions so that our partners are not only optimizing for the short-term future but also hold true values for the long run.”

The Siegfried Group is a global life sciences company with 11 sites in Europe, the USA, and Asia. The company is offering contract development and manufacturing of pharmaceutical APIs, intermediates and drug products. Parallel to other global-leading pharmaceutical companies, scientific development and R&D hold a core position in its business model. 

A drug substance is the part of any medication that produces the intended health effects. At the same time, it is required to be mixed with one or more other ingredients and formulated in a drug product under a finished dosage form (e.g., tablet, capsule, solution). Siegfried is one of a few companies worldwide that can provide an integrated solution for manufacturing both drug substances and drug products.

As a massive-scale company, Siegfried recognizes its capability and influence of utilizing resources during manufacturing. Jurgen Roos, Chief Scientist of Siegfried, affirms, “Sustainability plays an important role in our industry, and it is central to Siegfried‘s purpose and the value we create for our stakeholders. With our expertise in process optimization, we help our customers to develop greener production processes for their products and to achieve their ambitious sustainability targets.” With the company’s expertise in R&D, Siegfried supports its partners and customers to meet ambitious sustainability targets by applying green chemistry, reducing waste by minimizing solvent and reagent use, and decreasing energy consumption by implementing modern technologies. For instance, Siegfried improved the traditional mixture method of distilling the solvent by employing membrane technology such as microfiltration to reduce the solution’s concentration.

Aiming to ensure the stability of the supply chain of medicines, Siegfried believes that the production of drugs must be geographically decentralized. In the past 13 years, the company preserved its high-quality services and expanded its reach to seven countries on three continents. 

In 2023, Siegfried is celebrating its 150th anniversary. The company intends to expand its leadership position further and become the most trusted partner of the pharmaceutical industry, leading the optimization of pharmaceutical production processes worldwide and taking upon the social responsibility of reducing its carbon footprint by 50% by 2030.